PPAR-γ Agonists for the Treatment of Major Depression: A Review

Pharmacopsychiatry

Volumn 50, Issue 2, 2017, Pages 49-55

  Colle, R ^a,b,c   De Larminat, D ^a,b,c   Rotenberg, S ^a,b,c   Hozer, F ^a,b,c   Hardy, P ^a,b,c   Verstuyft, C ^a,d,e   Feve B ^f,g,h   Corruble, E ^a,b,c  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c Service de Psychiatrie   (France)

^d INSERM U1184   (France)

^e Service de Génétique Moléculaire   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g Imagine Institut Hospital Universitaire Necker   (France)

^h HÔPITAL SAINT ANTOINE   (France)

Author keywords

efficacy; major depression; pioglitazone; PPAR agonists; safety

Indexed keywords

BIOLOGICAL MARKER; FLUOXETINE; GLUCOSE; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDEPRESSANT AGENT; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLURRED VISION; DECREASED APPETITE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INCREASED APPETITE; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MYALGIA; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL DYSFUNCTION; TREATMENT DURATION; AGONISTS; DEPRESSIVE DISORDER, MAJOR; DIET RESTRICTION; GLUCOSE TOLERANCE TEST; METABOLISM;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; BLOOD GLUCOSE; DEPRESSIVE DISORDER, MAJOR; FASTING; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 85006355937     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0042-120120     Document Type: Article

References (64)

1. Thomas S. J., Shin M., McInnis M. G. et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy: 2015; 35 433 449
2. McIntyre R. S., Filteau M. J., Martin L. et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord.: 2014; 156 1 7
3. Perlis R. H., Ostacher M. J., Patel J. K. et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry.: 2006; 163 217 224
4. Consoli A., Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab: 2013; 15 967 977
5. Kapadia R., Yi J. H., Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci.: 2008; 13 1813 1826
6. Garcia-Bueno B., Perez-Nievas B. G., Leza J. C. Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases? Int J Neuropsychopharmacol: 2010; 13 1411 1429
7. Lincoff A. M., Tardif J. C., Schwartz G. G. et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA: 2014; 311 1515 1525
8. Kovacs P., Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab: 2005; 19 625 635
9. Tontonoz P., Spiegelman B. M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem.: 2008; 77 289 312
10. Loke Y. K., Kwok C. S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ: 2011; 342 d1309
11. Rosen C. J. Revisiting the rosiglitazone story-lessons learned. N Engl J Med.: 2010; 363 803 806
12. Dormandy J. A., Charbonnel B., Eckland D. J. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet: 2005; 366 1279 1289
13. Dormandy J. A., Betteridge D. J., Schernthaner G. et al. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis: 2009; 202 272 281
14. Erdmann E., Dormandy J. A., Charbonnel B. et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol.: 2007; 49 1772 1780
15. Erdmann E., Charbonnel B., Wilcox R. G. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care.: 2007; 30 2773 2778
16. Mazzone T., Meyer P. M., Feinstein S. B. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA: 2006; 296 2572 2581
17. Nissen S. E., Nicholls S. J., Wolski K. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA: 2008; 299 1561 1573
18. Wilcox R., Bousser M. G., Betteridge D. J. et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke: 2007; 38 865 873
19. Schernthaner G., Currie C. J., Schernthaner G. H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care: 2013; 36 Suppl 2 S155 S161
20. van Wijk J. P., de Koning E. J., Martens E. P. et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol.: 2003; 23 1744 1749
21. Doehner W., Erdmann E., Cairns R. et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol.: 2012; 162 20 26
22. Domecq J. P., Prutsky G., Leppin A. et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab.: 2015; 100 363 370
23. Jacob A. N., Salinas K., Adams-Huet B. et al. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab.: 2007; 9 386 393
24. Lincoff A. M., Wolski K., Nicholls S. J. et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA: 2007; 298 1180 1188
25. Idris I., Warren G., Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med.: 2012; 172 1005 1011
26. Zhu Z. N., Jiang Y. F., Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone: 2014; 68 115 123
27. Rosa A. O., Kaster M. P., Binfare R. W. et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry.: 2008; 32 1549 1556
28. Eissa Ahmed A. A., Al-Rasheed N. M., Al-Rasheed N. M. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol.: 2009; 20 635 642
29. Sadaghiani M. S., Javadi-Paydar M., Gharedaghi M. H. et al. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res.: 2011; 224 336 343
30. Kemp D. E., Ismail-Beigi F., Calabrese J. R. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry.: 2009; 166 619
31. Roohafza H., Shokouh P., Sadeghi M. et al. A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial. Int Sch Res Notices: 2014; 2014 697617
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.: 1960; 23 56 62
33. Trivedi M. H., Rush A. J., Ibrahim H. M. et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med.: 2004; 34 73 82
34. Rasgon N. L., Kenna H. A., Williams K. E. et al. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal: 2010; 10 321 328
35. Kemp D. E., Ismail-Beigi F., Ganocy S. J. et al. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord.: 2012; 136 1164 1173
36. Kemp D. E., Schinagle M., Gao K. et al. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs: 2014; 28 571 581
37. Hu Y., Xing H., Dong X. et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med: 2015; 10 1109 1114
38. Sepanjnia K., Modabbernia A., Ashrafi M. et al. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology: 2012; 37 2093 2100
39. Kashani L., Omidvar T., Farazmand B. et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology: 2013; 38 767 776
40. Zeinoddini A., Sorayani M., Hassanzadeh E. et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety.: 2015; 32 167 173
41. Lin K. W., Wroolie T. E., Robakis T. et al. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res.: 2015; 230 846 852
42. Matthews L., Berry A., Tersigni M. et al. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology: 2009; 150 75 86
43. Kotake D., Hirasawa N. Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes. Eur J Pharmacol.: 2013; 707 95 103
44. Iqbal S., Naseem I. Role of vitamin A in type 2 diabetes mellitus biology: effects of intervention therapy in a deficient state. Nutrition: 2015; 31 901 907
45. Lu J. M., Li J. Y., Pan C. Y. et al. Changes in pituitary-adrenal function in diabetics and their response to aminoglutethimide. Chin Med J (Engl): 1988; 101 587 590
46. Sonino N., Fava G. A. Erratum to CNS drugs in Cushing's disease: pathophysiological and therapeutic implications for mood disorders [Prog. Neuro-Psycol. Biol. Psychiatry, 26, 763 (2002)]. Prog Neuropsychopharmacol Biol Psychiatry.: 2002; 26 1011 1018
47. Pan A., Keum N., Okereke O. I. et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care.: 2012; 35 1171 1180
48. Vancampfort D., Correll C. U., Wampers M. et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med.: 2014; 44 2017 2028
49. Rhee S. J., Kim E. Y., Kim S. H. et al. Subjective depressive symptoms and metabolic syndrome among the general population. Prog Neuropsychopharmacol Biol Psychiatry.: 2014; 54 223 230
50. Corruble E., El Asmar K., Trabado S. et al. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry.: 2015; 14 366 367
51. Bellucci PN, Gonzalez Bagnes MF, Di Girolamo G et al. Potential effects of nonsteroidal anti-inflammatory drugs in the prevention and treatment of type 2 diabetes mellitus. J Pharm Pract 2016 [Epub ahead of print]
52. Kohler O., Benros M. E., Nordentoft M. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry: 2014; 71 1381 1391
53. Kohler O., Krogh J., Mors O. et al. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr Neuropharmacol.: 2016; 14 732 742
54. Chen Y. C., Wu J. S., Tsai H. D. et al. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol Neurobiol.: 2012; 46 114 124
55. Moreno S., Farioli-Vecchioli S., Ceru M. P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience: 2004; 123 131 145
56. Skerrett R., Pellegrino M. P., Casali B. T. et al. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor gamma Agonist Treatment Reduces Amyloid beta Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem.: 2015; 290 21591 21602
57. Carta A. R. PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr Drug Targets.: 2013; 14 743 751
58. Lecca D., Nevin D. K., Mulas G. et al. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARgamma agonist in vitro and in MPTP-treated mice. Neuroscience: 2015; 302 23 35
59. Gold P. W., Licinio J., Pavlatou M. G. Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-gamma systems. Mol Psychiatry.: 2013; 18 154 165
60. Wu J. S., Tsai H. D., Cheung W. M. et al. PPAR-gamma Ameliorates Neuronal Apoptosis and Ischemic Brain Injury via Suppressing NF-kappaB-Driven p22phox Transcription. Mol Neurobiol.: 2016; 53 3626 3645
61. Cimini A., Ceru M. P. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation. Stem Cell Rev.: 2008; 4 293 303
62. Sato T., Hanyu H., Hirao K. et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging.: 2011; 32 1626 1633
63. Brundin P., Wyse R. Parkinson disease: laying the foundations for disease-modifying therapies in PD. Nat Rev Neurol: 2015; 11 553 555
64. Pershadsingh H. A., Heneka M. T., Saini R. et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation: 2004; 1 3